Trials / Completed
CompletedNCT03335852
Safety and Pharmacokinetics of Abicipar Pegol Intravitreal Injections in Japanese Patients With Neovascular AMD
Evaluation of Safety and Systemic Pharmacokinetics After Abicipar Pegol (AGN-150998) Intravitreal Injections in Japanese Patients With NEovascular Age-Related Macular Degeneration (PINE Study)
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 11 (actual)
- Sponsor
- Allergan · Industry
- Sex
- All
- Age
- 50 Years
- Healthy volunteers
- Not accepted
Summary
This study will evaluate the safety and to characterize the systemic pharmacokinetics of free and vascular endothelial growth factor (VEGF)-bound abicipar following multiple monthly intravitreal injections of abicipar in Japanese patients with neovascular age-related macular degeneration (AMD).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Abicipar pegol | Abicipar pegol 2 mg administered to the study eye by intravitreal injection |
Timeline
- Start date
- 2017-11-28
- Primary completion
- 2018-10-08
- Completion
- 2018-10-08
- First posted
- 2017-11-08
- Last updated
- 2018-11-01
Locations
5 sites across 1 country: Japan
Source: ClinicalTrials.gov record NCT03335852. Inclusion in this directory is not an endorsement.